Terms: = Lung cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Clinical Outcome
15 results:
1. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract] [Full Text] [Related]
2. The Influence of kdr Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract] [Full Text] [Related]
3. The svegfr1-i13 splice variant regulates a β1 integrin/vegfr autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
Abou Faycal C; Brambilla E; Agorreta J; Lepeltier N; Jacquet T; Lemaître N; Emadali A; Lucas A; Lacal PM; Montuenga L; Pio R; Gazzeri S; Eymin B
Br J Cancer; 2018 Jun; 118(12):1596-1608. PubMed ID: 29795310
[TBL] [Abstract] [Full Text] [Related]
4. clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
[TBL] [Abstract] [Full Text] [Related]
5. The vegfr2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
Butkiewicz D; Krześniak M; Drosik A; Giglok M; Gdowicz-Kłosok A; Kosarewicz A; Rusin M; Masłyk B; Gawkowska-Suwińska M; Suwiński R
Int J Cancer; 2015 Nov; 137(10):2332-42. PubMed ID: 25975224
[TBL] [Abstract] [Full Text] [Related]
6. Increased vegfr-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
Yang F; Tang X; Riquelme E; Behrens C; Nilsson MB; Giri U; Varella-Garcia M; Byers LA; Lin HY; Wang J; Raso MG; Girard L; Coombes K; Lee JJ; Herbst RS; Minna JD; Heymach JV; Wistuba II
Cancer Res; 2011 Aug; 71(16):5512-21. PubMed ID: 21724587
[TBL] [Abstract] [Full Text] [Related]
7. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
Blumenschein GR; Reck M; Fossella F; Stewart DJ; Lathia C; Peña C
Cancer Biomark; 2011-2012; 10(6):287-98. PubMed ID: 22820084
[TBL] [Abstract] [Full Text] [Related]
8. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Feng Y; Wang W; Hu J; Ma J; Zhang Y; Zhang J
Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
[TBL] [Abstract] [Full Text] [Related]
9. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
[TBL] [Abstract] [Full Text] [Related]
10. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract] [Full Text] [Related]
11. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
Hirashima Y; Yamada Y; Matsubara J; Takahari D; Okita N; Takashima A; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Cancer Sci; 2009 Feb; 100(2):310-5. PubMed ID: 19068081
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, vegfr-1 and vegfr-2 levels in the sera of small cell lung cancer patients.
Ustuner Z; Saip P; Yasasever V; Vural B; Yazar A; Bal C; Ozturk B; Ozbek U; Topuz E
Med Oncol; 2008; 25(4):394-9. PubMed ID: 18317954
[TBL] [Abstract] [Full Text] [Related]
13. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract] [Full Text] [Related]
14. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract] [Full Text] [Related]
15. Novel targets for therapeutic agents in small cell lung cancer.
Ma PC; Salgia R
J Natl Compr Canc Netw; 2004 Mar; 2(2):165-72. PubMed ID: 19777705
[TBL] [Abstract] [Full Text] [Related]
